“EVERLAST-A: A Phase 2a Study Design of ORKA-001, a Novel Half-Life Extended IL-23p19 Monoclonal Antibody for Plaque Psoriasis” (2025) SKIN The Journal of Cutaneous Medicine, 9(6), p. s633. doi:10.25251/jg65bt44.